Analgesic effects of low-dose intravenous orphenadrine in the state of capsaicin hyperalgesia: A randomised, placebo-controlled, double-blind cross-over study using laser somatosensory evoked potentials obtained from capsaicin-irritated skin in healthy volunteers

Arzneimittel-Forschung/Drug Research

Volumn 54, Issue 10, 2004, Pages 673-679

  Schaffler, Klaus ^a   Reitmeir, Peter ^b  

^a HPR Human Pharmacodynamic Research GmbH   (Germany)

^b HPR Hum Pharmacodynamic Res GmbH ^*

Author keywords

CAS 4682 36 4; H1 antagonist; Hyperalgesia, capsaicin induced; Laser somatosensory evoked potentials; Orphenadrine, antihistaminergic effect, central analgesic effect

Indexed keywords

CAPSAICIN; ORPHENADRINE CITRATE; PLACEBO;

ADULT; ANALGESIC ACTIVITY; ARTICLE; CARBON DIOXIDE LASER; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; EDEMA; ELECTROENCEPHALOGRAM; ERYTHEMA; EVENT RELATED POTENTIAL; EVOKED SOMATOSENSORY RESPONSE; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPERALGESIA; LOW DRUG DOSE; MALE; NEUROGENIC INFLAMMATION; NORMAL HUMAN; PAIN; PERIPHERAL NERVOUS SYSTEM; RANDOMIZED CONTROLLED TRIAL; SKIN; SKIN MANIFESTATION;

EID: 7044254508     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1297020     Document Type: Article

References (46)

1. Bakris, G. L., Mulopulos, B. B., Tiwari, S. et al, Orphenadrine citrate: An effective alternative for muscle contraction headaches. III. Med. J. 161, 106 (1982)
2. Battermann, R. C., Methodology of analgesic evaluation: experience with orphenadrine citrate compound. Curr. Ther. Res. 7, 639 (1965)
3. Bellville, J. W., Dorey, F., Capparell, D. et al., Analgesic effects of hydroxyzine compared to morphine in man. J. clin. Pharmacol. 19, 290 (1979)
4. Berthold, C. W., Clinical evaluation of H1-receptor and H2-receptor antagonists for acute postoperative pain. J. Clin. Pharmacol. 33, 944-948 (1993)
5. Birkeland, I. W. J., Drug combinations with orphenadrine for pain relief associated with muscle spasm. Clin. Pharmacol. Ther. 9, 639 (1968)
6. Casale, R., Reduction of spastic hypertonia in patients with spinal cord injury: a double-blind comparison of intravenous orphenadrine citrate and placebo. Arch. Physical Med. Rehabil. 76, 660 (1995)
7. Cronheim, G., Pharmacological observations with orphenadrine hydrochloride. J. Pharmacol. Exp. Ther. 16A, 122 (1985)
8. Diamond, B. I., Bluhm, R. E., Borison, R. L. et al., Brain histamine: an endogenous system for mediating pain? Anaesthesiology 55, A286 (1981)
9. Drug Evaluations. Am. Med. Assoc. 208, 235 (1986)
10. Fry, E. N., Postoperative analgesia using papaveretum and orphenadrine. A preliminary trial. Anaesthesia 34, 281 (1979)
11. Gilbert, M. M., Analgesic/calmative effects of acetaminophen and phenyltoloxamine in treatment of simple nervous tension accompanied by headache. Curr. Ther. Res. 20, 53 (1976)
12. Ginzel, K. H., The blockade of reticular and spinal facilitation of motor function by orphenadrine. J. Pharmacol. Exp. Ther. 154, 128 (1966)
13. Ginzel, K. H., The effect of orphenadrine on neuromuscular transmission. Proc. West Pharmacol. Soc. 8, 19 (1965)
14. Gold, R. H., Treatment of low back syndrome with oral orphenadrine citrate. Curr Ther. Res. 23, 271 (1978)
15. Hill, S. J., Distribution, properties, and functional characteristics of three classes of histamine receptor. Pharmacol. Rev. 42, 45 (1990)
16. Hingorani, K., Orphenadrine-paracetamol in backache - a double-blind controlled trial. Br. J. Clin. Pract. 25, 227 (1971)
17. Hunskaar, S., Donnell, D., Clinical and pharmacological review of the efficacy of orphenadrine and its combination with paracetamol in painful conditions. J. Int. Med. Res. 19, 71 (1991)
18. Hunskaar, S., Mechanisms of orphenadrine induced antinociception in mice: a role for serotonergic pathways. Eur. J. Pharmacol. 160, 83 (1989)
19. Kantor, T. G., Steinberg, F. P., Studies of tranquilizing agents and meperidine in clinical pain. In: J. J. Bonica (eds.), Advances in pain research and therapy, vol. 1, pp. 567-572. Raven Press, New York (1976)
20. Katzenschlager, R., Sampaio, C., Costa, J. et al., Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst. Rev. (2) CD003735 (2003)
21. Klotz, U., Tramadol - the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. Arzneim.-Forsch./Drug Res. 53, 681 (2003)
22. Kornhuber, J., Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies. J. Neural Transm. Gen. Sect. 102, 237 (1995)
23. Martindale, The Extrapharmacopoeia, pp. 539-540, The Pharmaceutical Press, London (1989)
24. Mok, M. S., Drug combinations with orphenadrine. Clin. Ther. 2, 188 (1979)
25. Moore, R. A., McQuay, H. J., Single-patient data meta-analysis of 3453 postoperative patients: oral tramadol versus placebo, codeine and combination analgesics. Pain 69, 287 (1997)
26. Ninkovic, M., Hunt, S. P., Opiate and histamine H1 receptors are present on some substance P-containing dorsal root ganglion cells. Neurosci. Lett. 53, 133 (1985)
27. Ninkovic, M., Hunt, S. R, Cleave, J. R., Localisation of opiate and histamine H1 receptors in the primate sensory ganglia and spinal cord. Brain Res. 241, 197 (1982)
28. Onuaguluchi, G., Some aspects of the pharmacology of orphenadrine. J. Pharm. Pharmacol. 15, 329 (1963)
29. Palacios, J. M., Pipkin, M. A., Woodward, D. F., The distribution of histamine H1 receptors in the rat brain, an autoradiographic study. Neuroscience 6, 15 (1981)
30. Pubill, D., Assessment of the adrenergic effects of orphenadrine in rat vas deferens. J. Pharm. Pharmacol. 51, 307 (1999)
31. Putt, M., Chinchilli, V. M., A mixed effects model for the analysis of repeated measures cross-over studies. Stat. Med. 18, 3037 (1999)
32. Raffa, R. B., Antihistamines as analgesics. J. Clin. Pharm. Ther. 26, 81 (2001)
33. Roozemond, R. C., The effect of orphenadrine and its N-demethyl derivative on the level of 5-hydroxytryptamine in rat brain. Int. J. Neuropharmacol. 5, 413 (1966)
34. Roozemond, R. C., Hespe, W., Nauta, W. T., The concentrations of orphenadrine and its N-demethylated derivatives in rat brain after intraperitoneal administration of orphenadrine and tofenacine. Int. J. Neuropharmacol. 7, 293 (1968)
35. Rumore, M. M., Schlichting, D. A., Analgesic effects of antihistaminics. Life Sci. 36, 403 (1985)
36. Rumore, M. M., Schlichting, D. A., Clinical efficacy of antihistaminics as analgesics. Pain 25, 7 (1986)
37. Schaffler, K., Seibel, K., Thomsen, M. et al., Effect of the new H1-antagonist ReN1869 on capsaicin induced hyperalgesia in human skin. Arzneim.-Forsch./Drug Res. 54, 187 (2004)
38. Schaffler, K., Wauschkuhn, C. H., Brunnauer, H., Rehn, D., Evaluation of the local anaesthetic activity of dimethindene maleate by means of laser algesimetry in healthy volunteers. Arzneim.-Forsch./Drug Res. 42 (II), 1332 (1992)
39. Schaffler, K., Wauschkuhn, C. H., Gierend, M., Analgesic potency of a new anticonvulsant drug versus acetylsalicylic acid via laser somatosensory evoked potentials. Randomised placebo-controlled double blind (5-way) crossover study. Arzneim.-Forsch./Drug Res. 41 (I), 427 (1991)
40. Schaffler, K., Wauschkuhn, C. H., Martinelli, M. et al., Influences of dimethindene maleate in a new formulation on oculo- and psychomotor performance using the oculodynamic test (ODT) in volunteers. Agents Actions 41, C136 (1994)
41. Schwartz, J. C., Barbin, G., Duchemin, A. M. et al., Histamine receptors in the brain: characterization by binding studies and biochemical effects, Adv. Biochem. Psychopharmacology 21, 169 (1980)
42. Sureda, F. X., In vitro and in vivo protective effect of orphenadrine on glutamate neurotoxicity. Neuropharmacology 38, 671 (1999)
43. Syvälathi E. K., Kunelius, R., Lauren L., Effects of antiparkinsonian drugs on muscarinic receptor binding in rat brain, heart and lung. Pharmacol. Toxicol. 62, 90 (1988)
44. Thomsen, M. S., Hansen, A. J., Olsen, U. B. et al., Effects of ReN1869 on capsaicin and histamine induced neurogenic inflammation in healthy subjects. Drug Dev. Res. 57, 193 (2002)
45. Uitz, E., Diclofenac/Orphenadrin-Infusionstherapie bei Patienten mit aktivierten Arthrosen. (Diclofenac/orphenadrine infusion therapy in patients with active arthrosis). Wien. Med. Wochenschr. 148, 179 (1998)
46. Winter, L., Analgesic combinations with orphenadrine in oral post-surgical pain. J. Int. Med. Res. 7, 240 (1979)